{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:08Z","timestamp":1791925748089,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cholinesterase inhibitors (ChEIs) are prescribed for Alzheimer\u2019s disease (AD) and sometimes for mild cognitive impairment (MCI) without knowing underlying pathologies and its effect on cognition. We investigated the frequency of ChEI prescriptions in amyloid-negative MCI and their association with cognitive changes in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included participants with amyloid positron emission tomography (PET)-negative MCI from the ADNI. We analyzed the associations of ChEI use with cognitive changes, brain volume, and cerebrospinal fluid (CSF) total tau (t-tau), hyperphosphorylated tau<jats:sub>181<\/jats:sub> (p-tau<jats:sub>181<\/jats:sub>), and p-tau<jats:sub>181<\/jats:sub>\/t-tau ratio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ChEIs were prescribed in 27.4% of amyloid PET-negative MCI and were associated with faster cognitive decline, reduced baseline hippocampal volume and entorhinal cortical thickness, and a longitudinal decrease in the frontal lobe cortical thickness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The association between ChEI use and accelerated cognitive decline may stem from underlying pathologies involving reduced hippocampal volume, entorhinal cortical thickness and faster frontal lobe atrophy. We suggest that ChEI use in amyloid PET-negative MCI patients might need further consideration, and studies investigating the causality between ChEI use and cognitive decline are warranted in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01580-y","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T12:02:08Z","timestamp":1727870528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes"],"prefix":"10.1186","volume":"16","author":[{"given":"Jung-Min","family":"Pyun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"3","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry","year":"2003","unstructured":"Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306(3):821\u20137. https:\/\/doi.org\/10.1124\/jpet.102.041616.","journal-title":"J Pharmacol Exp Ther"},{"key":"1580_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021;190: 108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352.","journal-title":"Neuropharmacology"},{"issue":"7","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141(7):1917\u201333. https:\/\/doi.org\/10.1093\/brain\/awy132.","journal-title":"Brain"},{"issue":"6","key":"1580_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF. Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules. 2022;27(6): 1816. https:\/\/doi.org\/10.3390\/molecules27061816.","journal-title":"Molecules"},{"issue":"2","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1517\/14728222.11.2.161","volume":"11","author":"U Holzgrabe","year":"2007","unstructured":"Holzgrabe U, Kapkov\u00e1 P, Alpt\u00fcz\u00fcn V, Scheiber J, Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets. 2007;11(2):161\u201379. https:\/\/doi.org\/10.1517\/14728222.11.2.161.","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","volume":"86","author":"G Pagano","year":"2015","unstructured":"Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(7):767\u201373. https:\/\/doi.org\/10.1136\/jnnp-2014-308764.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","volume":"17","author":"T van Laar","year":"2011","unstructured":"van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of cholinesterase inhibitors in Parkinson\u2019s disease dementia: a review of clinical data. CNS Neurosci Ther. 2011;17(5):428\u201341. https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00166.x.","journal-title":"CNS Neurosci Ther"},{"issue":"17","key":"1580_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179290","volume":"22","author":"\u0141J Walczak-Nowicka","year":"2021","unstructured":"Walczak-Nowicka \u0141J, Herbet M. Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their Pathogenesis. Int J Mol Sci. 2021;22(17): 9290. https:\/\/doi.org\/10.3390\/ijms22179290.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment. Neurology. 2018;90(3):126\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000004826.","journal-title":"Neurology"},{"issue":"1","key":"1580_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2010.343","volume":"68","author":"DLS Schneider","year":"2011","unstructured":"Schneider DLS, Insel MPS, Weiner DMW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer\u2019s Disease Neuroimaging Initiative. Arch Neurol. 2011;68(1):58. https:\/\/doi.org\/10.1001\/archneurol.2010.343.","journal-title":"Arch Neurol"},{"issue":"11","key":"1580_CR11","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a.","journal-title":"Neurology"},{"issue":"3","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502\u201316. https:\/\/doi.org\/10.1007\/s11682-012-9186-z.","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"1580_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517\u201327. https:\/\/doi.org\/10.1007\/s11682-012-9176-1.","journal-title":"Brain Imaging Behav"},{"issue":"3","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13(1):99. https:\/\/doi.org\/10.1186\/s13195-021-00836-1. Published 2021 May 10.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jalz.2010.03.004","volume":"6","author":"CR Jack","year":"2010","unstructured":"Jack CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Dement J Alzheimers Assoc. 2010;6(3):212\u201320. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.004.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"1580_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.nicl.2016.11.025","volume":"13","author":"L S\u00f8rensen","year":"2017","unstructured":"S\u00f8rensen L, Igel C, Pai A, et al. Differential diagnosis of mild cognitive impairment and Alzheimer\u2019s disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry. NeuroImage Clin. 2017;13:470\u201382. https:\/\/doi.org\/10.1016\/j.nicl.2016.11.025.","journal-title":"NeuroImage Clin"},{"issue":"4","key":"1580_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313. https:\/\/doi.org\/10.1002\/ana.21610.","journal-title":"Ann Neurol"},{"issue":"5","key":"1580_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-011-0808-0","volume":"121","author":"LM Shaw","year":"2011","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (Berl). 2011;121(5):597\u2013609. https:\/\/doi.org\/10.1007\/s00401-011-0808-0.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"1580_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14010041","volume":"14","author":"DF Weaver","year":"2024","unstructured":"Weaver DF. Thirty risk factors for Alzheimer\u2019s Disease Unified by a common neuroimmune\u2013neuroinflammation mechanism. Brain Sci. 2024;14(1): 41. https:\/\/doi.org\/10.3390\/brainsci14010041.","journal-title":"Brain Sci"},{"issue":"5","key":"1580_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/archneur.63.5.693","volume":"63","author":"LG Apostolova","year":"2006","unstructured":"Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps [published correction appears in Arch Neurol. 2007 Sep;64(9):1360-1]. Arch Neurol. 2006;63(5):693--699. https:\/\/doi.org\/10.1001\/archneur.63.5.693.","journal-title":"Arch Neurol"},{"issue":"1","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-017-0326-y","volume":"9","author":"JM Pyun","year":"2017","unstructured":"Pyun JM, Park YH, Kim HR, et al. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. Alzheimers Res Ther. 2017;9(1):99. https:\/\/doi.org\/10.1186\/s13195-017-0326-y. Published 2017 Dec 16.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099.","journal-title":"Brain"},{"issue":"12","key":"1580_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/s0006-3223(99)00306-6","volume":"47","author":"MP Laakso","year":"2000","unstructured":"Laakso MP, Frisoni GB, K\u00f6n\u00f6nen M, et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer\u2019s disease: a morphometric MRI study. Biol Psychiatry. 2000;47(12):1056\u201363. https:\/\/doi.org\/10.1016\/s0006-3223(99)00306-6.","journal-title":"Biol Psychiatry"},{"issue":"Pt 2","key":"1580_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/brain\/awq348","volume":"134","author":"KA Josephs Jr","year":"2011","unstructured":"Josephs KA Jr, Whitwell JL, Weigand SD, et al. Predicting functional decline in behavioural variant frontotemporal dementia. Brain. 2011;134(Pt 2):432\u201348. https:\/\/doi.org\/10.1093\/brain\/awq348.","journal-title":"Brain"},{"issue":"12","key":"1580_CR27","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/jamaneurol.2015.2061","volume":"72","author":"E Devenney","year":"2015","unstructured":"Devenney E, Bartley L, Hoon C, et al. Progression in behavioral variant Frontotemporal Dementia: a longitudinal study. JAMA Neurol. 2015;72(12):1501\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2015.2061.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1580_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaneurol.2023.2560","volume":"80","author":"A Costoya-S\u00e1nchez","year":"2023","unstructured":"Costoya-S\u00e1nchez A, Moscoso A, Silva-Rodr\u00edguez J, et al. Increased medial temporal tau Positron Emission Tomography Uptake in the absence of Amyloid-\u03b2 positivity. JAMA Neurol. 2023;80(10):1051\u201361. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2560.","journal-title":"JAMA Neurol"},{"issue":"22","key":"1580_CR29","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","volume":"81","author":"WT Hu","year":"2013","unstructured":"Hu WT, Watts K, Grossman M, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81(22):1945\u201352. https:\/\/doi.org\/10.1212\/01.wnl.0000436625.63650.27.","journal-title":"Neurology"},{"issue":"2","key":"1580_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [11\u00a0C]PIB-PET centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.001.","journal-title":"Alzheimers Dement"},{"issue":"Pt 3","key":"1580_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138(Pt 3):772\u201383. https:\/\/doi.org\/10.1093\/brain\/awu367.","journal-title":"Brain"},{"issue":"12","key":"1580_CR32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492\u2013501. https:\/\/doi.org\/10.1001\/jamaneurol.2017.2814.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T12:04:15Z","timestamp":1727870655000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01580-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study procedures were approved by the institutional review board of all participating centres ( ), and written informed consent was obtained from all participants or authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study procedures were approved by the institutional review board of all participating centres ( ), and written informed consent was obtained from all participants or authorized representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}